Skip to main content
Qualigen Therapeutics, Inc. logo

Qualigen Therapeutics, Inc. — Investor Relations & Filings

Ticker · QLGN ISIN · US74754R1032 US Professional, scientific and technical activities
Open in API
Filings indexed 618 across all filing types
Latest filing 2018-08-14 Earnings Release
Country US United States of America
Listing US QLGN

About Qualigen Therapeutics, Inc.

https://qlgntx.com/

Qualigen Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for cancer. The company's efforts are directed toward creating therapeutics for both adult and pediatric patients, with a particular emphasis on rare cancers and areas of high unmet medical need. Its development approach combines internal capabilities with collaborations from major cancer research institutions. The company's investigational oncology pipeline includes programs such as QN-302, a Pan-RAS inhibitor platform, and QN-247.

Recent filings

Filing Released Lang Actions
Earnings Release 2018
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The text specifically mentions Item 2.02, which relates to the Results of Operation and Financial Condition, and references a press release announcing financial results for the three- and six-month periods ended June 30, 2018. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes a press release as an exhibit. The length of the document is 3897 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, a short document that announces or furnishes a press release of financial results without containing the full financial data should be classified as an Earnings Release (ER). The document is not a full quarterly or interim report (IR), nor is it a regulatory filing of a different nature. Therefore, the appropriate classification is Earnings Release (ER).
2018-08-14 English
Interim / Quarterly Report 2018
Interim / Quarterly Report Q2 2018
2018-08-14 English
Board/Management Information 2018
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content specifically details the departure and appointment of key officers, including the appointment of a new CEO and the resignation of the previous CEO, along with related compensation and consulting agreements. This matches the description of Board/Management Information filings, which announce changes in the company's board of directors or senior management. The document is not a full financial report, earnings release, or other report type, but rather an announcement of management changes. Therefore, the appropriate classification is MANG (Board/Management Information). The document length and detail support a high confidence in this classification.
2018-07-02 English
PRIMARY DOCUMENT
Director's Dealing
2018-06-28 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 26, 2018, by Ritter Pharmaceuticals, Inc. It reports the submission of matters to a vote of security holders at the company's Annual Meeting, including election of directors and ratification of the appointment of the independent registered public accounting firm. The content focuses on voting results from the shareholder meeting. The document length is 4020 characters, which is relatively short and contains specific voting results. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. It is not an Annual Report, Audit Report, or Management Information, nor is it a report publication announcement. Therefore, the correct classification is DVA with high confidence.
2018-06-27 English
Board/Management Information 2018
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is the appointment of a new Chief Financial Officer, John W. Beck, including details about his background, compensation, and severance agreement. This fits the category of announcements related to changes in the company's board of directors or senior management. There are no financial statements or earnings data, so it is not an earnings release or financial report. The document is not a proxy statement, merger filing, or other categories. Therefore, the document is best classified as Board/Management Information (MANG). The confidence in this classification is high given the clear focus on management appointment and related agreements.
2018-05-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.